A flagella-less mutant of Borrelia burgdorferi as a live attenuated vaccine in the murine model of Lyme disease

Journal of Infectious Diseases

Volumn 173, Issue 5, 1996, Pages 1184-1193

  Šadžiene, Ariadna ^a,b   Thompson, Patricia A ^a   Barbour, Alan G ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; LIVE VACCINE;

ANIMAL MODEL; ARTICLE; BACTERIUM MUTANT; BORRELIA BURGDORFERI; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLAGELLUM; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INTRADERMAL DRUG ADMINISTRATION; LYME DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029898730     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.5.1184     Document Type: Article

References (13)

1. Barbour AG, Fish D. The biological and social phenomenon of Lyme disease. Science 1993;260:1610-6.
2. Erdile LF, Brandt MA, Warakomski DJ, et al. The role of attached lipid in the immunogenicity of Borrelia burgdorferi OspA. Infect Immun 1993;61:81-90.
3. Fikrig ES, Barthold S, Kantor FS, Flavell RA. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 1990;250:553-3.
4. Schaible UE, Kramer MD, Eichmann K, Modolell M, Museteanu C, Simon MM. Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc Natl Acad Sci USA 1990;87:3768-72.
5. Simon MM, Schaible UE, Kramer MD, et al. Recombinant outer surface protein A from Borrelia burgdorferi induces antibodies protective against spirochetal infection in mice. J Infect Dis 1991;164:123-32.
6. Stover CK, Bansal GP, Hanson MS, et al. Protective immunity elicited by recombinant bacille Calmette-Guérin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med 1993;178:197-209.
7. Keller D, Koster FT, Marks DH, Hosbasch P, Erdile LF, Mays JP. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA 1994;271:1764-8.
8. Kurashige S, Bissett M, Oshiro L. Characterization of a tick isolate of Borrelia burgdorferi that possesses a major low-molecular-weight surface protein. J Clin Microbiol 1990;28:1362-6.
9. Wilske B, Preac-Mursic V, Göbel UB, Graf B, Jauris S, Soutschek E. An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis. J Clin Microbiol 1993;31:340-50.
10. Jonsson M, Noppa L, Barbour AG, Bergström S. Heterogeneity of outer membrane proteins in Borrelia burgdorferi: comparison of osp operons of three isolates of different geographic origins. Infect Immun 1992;60:1845-53.
11. Rosa PA, Schwan T, Hogan D. Recombination between genes encoding major outer surface proteins A and B of Borrelia burgdorferi. Mol Microbiol 1992;6:3031-40.
12. Šadžiene A, Rosa PA, Thompson PA, Hogan DM, Barbour AG. Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and characterization. J Exp Med 1992;176:799-809.
13. Greene RT, Walker RL, Nicholson WL, et al. Immunoblot analysis of immunoglobulin G response to the Lyme disease agent (Borrelia burgdorferi) in experimentally and naturally exposed dogs. J Clin Microbiol 1988;26:648-53.